KCM
RCKT icon

Kingdon Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Kingdon Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-28,750
Closed -$1.08M – 139
2015
Q3 		$1.08M Buy
+28,750
New +$1.32M 0.05% 120

Other funds holding RCKT

DPA
Devon Park Associates $30.8M AUM 0.85% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Kingdon Capital Management's RCKT Position: Q4 2015 in Review

Kingdon Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q4 2015, closing a stake of 28,750 shares — an estimated $1.08M sold.

Kingdon Capital Management first reported a position in RCKT in Q3 2015 and held it in 1 quarter. The position peaked at $1.08M in Q3 2015. 60 funds tracked by Wall St. Rank hold RCKT as of Q4 2015.

  • Kingdon Capital Management reported no remaining Rocket Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Kingdon Capital Management sold 28,750 Rocket Pharmaceuticals shares in Q4 2015, an estimated $1.08M.
  • Kingdon Capital Management first reported a position in Rocket Pharmaceuticals in Q3 2015 and held it in 1 quarter.
  • Kingdon Capital Management's Rocket Pharmaceuticals position peaked at $1.08M in Q3 2015.
  • 60 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2015.

Based on Kingdon Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.